Skip to main content
About
Management
Board of Directors
Scientific Advisory Board
Business Development
Contact Us
Pipeline
Programs
KRAS G12C Inhibitor (MRTX849)
Sitravatinib (MGCD516)
Posters/Publications
Clinical Trials
Mirati Sponsored Trials
Collaboration Trials
Expanded Access Policy
(Compassionate Use)
Careers
Mission & Values
Investors
Overview
News Releases
Events & Presentations
Stock Information
Analyst Coverage
Financials & Filings
Corporate Governance
Investor FAQs
IR Contact
Emails Alerts
News Releases
Normal
Press release year list
2020
2019
2018
2017
2016
2015
2014
2013
11/23/2020
Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx Conference
11/05/2020
Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual Healthcare Conference
11/04/2020
Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights
10/30/2020
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
10/27/2020
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
10/26/2020
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
10/25/2020
Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data
10/15/2020
Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics (ENA)
9/18/2020
Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress
9/17/2020
Boehringer Ingelheim And Mirati Therapeutics Announce Clinical Collaboration To Study BI 1701963, A SOS1::pan-KRAS Inhibitor In Combination With MRTX849, A KRAS G12C Selective Inhibitor
9/03/2020
Mirati Therapeutics To Participate In Citi's 15th Annual Biopharma Virtual Conference
8/06/2020
Mirati Therapeutics Reports Second Quarter 2020 Financial Results And Recent Business Highlights
6/05/2020
Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference
5/18/2020
Mirati Therapeutics Appoints Joseph A. Leveque, M.D. As Chief Medical Officer
5/15/2020
Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II
5/07/2020
Mirati Therapeutics Reports First Quarter 2020 Financial Results And Recent Corporate Updates
2/25/2020
Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates
2/19/2020
Mirati Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/15/2020
Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Symposium
1/14/2020
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
1/09/2020
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
1/08/2020
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
1/06/2020
Mirati Therapeutics Announces Executive Management Changes
1/02/2020
Mirati Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference